Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer.
Schmitt
Manfred
M
Sweep
Fred C G J
FC
D018943:Anthracyclines / Q000378:metabolism / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017024:Chemotherapy, Adjuvant / Q000379:methods; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D010447:Peptide Hydrolases / Q000378:metabolism; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism*
D018943:Anthracyclines; D014408:Biomarkers, Tumor; D019715:Tissue Inhibitor of Metalloproteinase-1; D015251:Epirubicin; D003520:Cyclophosphamide; D010447:Peptide Hydrolases; D005472:Fluorouracil; D008727:Methotrexate